Universal Ibogaine Inc · TSXV:IBO
Universal Ibogaine — Investor Presentation (August 2021)
29 slides from Universal Ibogaine's investor presentation, August 2021
Slide 1: Universal Ibogaine – Investor Presentation
UNIVERSAL IBOGAINE – INVESTOR PRESENTATION CREATING THE GOLD STANDARD FOR ADDICTION TREATMENT WITH IBOGAINE ASSISTED PSYCHOTHERAPY AUGUST 2021 Clear Sky Recovery Clinic Operating Brand. 1
Slide 2: Disclaimer and Use of Forward-Looking Statements
DISCLAIMER AND USE OF FORWARD-LOOKING STATEMENTS This presentation is provided for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities. It has been provided solely to
Slide 3: Universal Ibogaine
UNIVERSAL IBOGAINE Building a network of holistic recovery clinics focusing on the medical, scientific and authorized application of ibogaine to treat the roots of addiction. Born of Holistic Healing, Backed By Science. 3
Slide 4: Our Mission, Vision & Value Proposition
OUR MISSION, VISION & VALUE PROPOSITION MISSION To treat the roots of addiction effectively using ibogaine and other psychedelic medicines. VISION Creating the global standard for addiction treatment with ibogaine-assisted psychotherapy. VALUE PROPOSITION To provide those living with addiction the b
Slide 5: Background to the Financing
BACKGROUND TO THE FINANCING Universal Ibogaine Inc. (“UI”) is a private company whose strategy involves: • The development of a network of addiction treatment clinics, and • applying to Health Canada to undertake clinical trials (commencing in 2021) of ibogaine for use in addiction treatment therapy
Slide 6: The Problem: Addiction (Closely Intertwined with the Mental Health Crisis)
THE PROBLEM: ADDICTION (CLOSELY INTERTWINED WITH THE MENTAL HEALTH CRISIS) 2 HOURS 1 IN 5 The average time that passes The number of Canadians who between deaths in Canada by illicit suffer from addiction in any drug overdose. given year. 50% 93% of Canadians will be affected by increase in overdose
Slide 7: Therapeutic Responses to Addiction Remain Inadequate
THERAPEUTIC RESPONSES TO ADDICTION REMAIN INADEQUATE Typical treatments are temporary, Have low effectiveness and high relapse rates. Current reliance on substitution therapies, with addictive properties. Lifelong recovery is possible. Psychedelic medicinal alternatives and therapeutic healing modal
Slide 8: The Opportunity of Psychedelic Medicine
THE OPPORTUNITY OF PSYCHEDELIC MEDICINE Company Valuations Widespread acknowledgement Increasing awareness of that psychedelics enhance psychedelics as an treatment approaches to: alternative to traditional medicinal approaches. Increased investment fueling the “next - Opioid Addiction generation” o
Slide 9: Ibogaine: Efficacy in Addiction Treatment
IBOGAINE: EFFICACY IN ADDICTION TREATMENT • Ibogaine is a naturally-occurring molecule originally derived from the root bark of a shrub found in the Congo Basin. • Powerful addiction-interrupting psychedelic. • Regulates dopamine re-uptake and many other neurotransmitter systems. • Metabolizes into
Slide 10: Ibogaine: Safety Consideration Requiring Experienced Management
IBOGAINE: SAFETY CONSIDERATION REQUIRING EXPERIENCED MANAGEMENT • Clear Sky Cancun was founded in 2003 with more than 3500 treatments to date. • Our licensing agreement with Clear Sky Cancun gives us exclusive rights to their safety protocol. • Dr Alberto Sola has treated more people with ibogaine t
Slide 11: Our Pathway to Ibogaine
OUR PATHWAY TO IBOGAINE Universal Ibogaine (Public Holding Company) Clear Sky Recovery (Brand and IP Ownership) Strictly Confidential UU) TRACK 1: (i) * Clinical Trials Approval in Canada * Clinical Trial Application leading to Phase 1-3 clinical trials in Canada TRACK 2: Develop Holistic Psychother
Slide 12: Holistic Recovery Clinics: Near Term in Canada
HOLISTIC RECOVERY CLINICS: NEAR TERM IN CANADA • Residential suburban/rural recovery centres • Innovative non-psychedelic detox methods • Residential aftercare post treatment • Holistic treatment programs • Revenue in year 1 12
Slide 13: Ibogaine Clinical Trials
IBOGAINE CLINICAL TRIALS We are preparing our Clinical Trials Application which: • Should be informed by the Clear Sky Cancun data and treatment protocol (more than 3,500 treatments to date). • Intended to be the basis for authorizing its medical use in Canada and ultimately other G7 countries. • Wi
Slide 14: From Private to Public
FROM PRIVATE TO PUBLIC Why go public now? To enable public participation in an ibogaine-focused company incorporating: • Clinical trials for ibogaine in Canada toward medicalization. • Innovative, pre-ibogaine, addiction treatment in Canada and potentially other G-7 jurisdictions. • Exploration of p
Slide 15: The Canada Advantage
THE CANADA ADVANTAGE Medicalized Ibogaine G7 Canadian clinical trial country entry through Canada infrastructure accessible to is driven by: Universal Ibogaine and inspired by real world data amassed at Clear Sky. (Runway to) (Accelerated/ REGULATION Harmonized) RESEARCH Faster potential runway to c
Slide 16: Our Addressable Canadian Market
OUR ADDRESSABLE CANADIAN MARKET 16
Slide 17: Our Competitive Edge
OUR COMPETITIVE EDGE Clear Sky Recovery: The leading brand combining the best of • Atai/Compass Pathways available addiction know-how with • Gilgamesh medicalized ibogaine. • MindMed Conventional Psychedelic Drug Treatments Development for Addiction • Sunshine Coast HC • GreenStone • Wholeness Clini
Slide 18: Operational Build Out
OPERATIONAL BUILD OUT 2021 2023 2025 • Initial Clinic Acquisition • Phase 2 Clinical Trial concluded. • Ibogaine medicalization in (Manitoba). • Clinics build-out in Canada, other Canada. • Phase 1 Clinical Trial Application. G-7 and overseas. • Roll-out into built-out clinics. • Clinics build-out i
Slide 19: Capital Raise and Proposed Use of Funds
CAPITAL RAISE AND PROPOSED USE OF FUNDS 19
Slide 20: Capital Structure - Shares Issued
CAPITAL STRUCTURE - SHARES ISSUED 20
Slide 21: Capital Structure - Additional Shares Reserved for Issue
CAPITAL STRUCTURE - ADDITIONAL SHARES RESERVED FOR ISSUE 21
Slide 22: Our Company Founders
OUR COMPANY FOUNDERS Shayne Nyquvest is a legend in Dr Sola has treated Canadian finance. Shayne was a more patients with managing partner of Canaccord ibogaine detox therapy Genuity. than any other person in the world. Shayne has been involved in over 400 public company financings His clinic has in
Slide 23: Our Leadership Team
OUR LEADERSHIP TEAM Dr Rami Batal, MBA, Pharm.D – Chief Executive Officer Dr. Rami Batal is a seasoned biopharmaceutical industry executive and a healthcare professional who has a passion for, and expertise and experience in, neuropsychiatry and mental health/behavioral health illnesses, including s
Slide 24: Our Board of Directors
OUR BOARD OF DIRECTORS Alberto Sola, MD - Co-Founder & President Clear Sky Addiction Solution’s President, Dr Sola is a thought leader in entheogenic treatment. He has the distinction of having treated more patients with ibogaine than any other person in the world and is head of operations at Clear
Slide 25: Robert Turner and Marilyn Loewen Mauritz - Directors
Robert Turner, ICD.D, MBA - Director Mr. Turner is President of his own incorporated consulting firm and a Principal within Western Management Consultants (WMC). His consulting focus is providing guidance to Boards on their governance including proper CEO oversight. Mr. Turner brings experience as a
Slide 26: Statutory Rights of Action for Damages or Rescission for Canadian Investors
STATUTORY RIGHTS OF ACTION FOR DAMAGES OR RESCISSION FOR CANADIAN INVESTORS Securities legislation in certain of the provinces of Canada provides purchasers with rights of rescission or damages, or both, where an offering memorandum or any amendment to it contains a misrepresentation. A “misrepresen
Slide 27: Rights not available for certain purchasers
These rights are not available for a purchaser that is (a) a Canadian financial institution or a Schedule III Bank (each as defined in National Instrument 45-106 – Prospectus Exemptions), (b) the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Cana
Slide 28: Statutory right of action limitations
This statutory right of action is subject to the following: (a) if you elect to exercise the right of action for rescission, you will have no right of action for damages against the Company; (b) except with respect to purchasers resident in Nova Scotia, no action shall be commenced to enforce a righ
Slide 29: Freedom From Addiction Is Possible
Freedom From Addiction Is Possible THANK YOU www.UniversalIbogaine.com Contact: Rami.Batal@UniversalIbogaine.com July 2021
Universal Ibogaine — Investor Presentation (August 2021) on 6ix